China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced plans to present new and updated data from the sovleplenib ESLIM-01 Phase III trial, along with several investigator-initiated studies of compounds discovered by HutchMed, at the American Society of Hematology (ASH) Annual Meeting and the European Society for Medical Oncology (ESMO) Asia Congress 2024 next month.
Long-Term Efficacy and Safety of Solvleplenib in Chronic Primary ITP
The follow-on sub-study data demonstrated that long-term treatment with sovleplenib was effective in increasing and maintaining platelet count in adults with chronic primary immune thrombocytopenia (ITP) in China. The drug achieved an overall response rate of 81% (145/179) in the overall population, with durable response rates at 51.4% and long-term durable response rates at 59.8%. The median cumulative duration of platelet count ≥50×10⁹/L was 38.9 weeks. The long-term treatment was well tolerated, with a safety profile consistent with previous studies, and no new safety signals were identified.
Sovleplenib’s Targeting of Syk in Hematological Malignancies and Auto-immune Diseases
Sovleplenib is a novel, selective, oral inhibitor targeting spleen tyrosine kinase (Syk), under development for the treatment of hematological malignancies and auto-immune diseases. Syk is a major component in B-cell receptor and Fc receptor (FcR) signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders, including ITP. The drug has earned breakthrough therapy designation and priority review statuses in China for this indication. The ESLIM-01 trial has previously met all endpoints.- Flcube.com
